Table 5.
Summary of high-frequency tumor mutations (≥10%) by NGS with UCSF500 panel
| Alteration in UCSF500 panel (19, 20) | Incidence of mutation in pooled phase I and II study NGS cohort | Median TTP (95% CI), months | p value | Median OS (95% CI), months | p value |
|---|---|---|---|---|---|
| Overall NGS cohort (n = 24) | − | 2.88 (1.71, 4.67) | − | 13.87 (7.59, 24.39) | − |
| TP53 | 0.67 | 2.07 (1.38, 5.32) | 0.55 | 13.87 (6.93, 24.39) | 0.80 |
| TERT promoter | 0.38 | 3.45 (0.85, 4.67) | 0.33 | 14.86 (3.32, 40.80) | 0.77 |
| mTOR pathway | 0.46 | 1.94 (0.85, 5.52) | 0.49 | 9.27 (2.99, 15.22) | 0.12 |
| WNT pathway | 0.42 | 3.45 (0.85, 4.67) | 0.95 | 7.7 (2.99, 26.79) | 0.06 |
| KMT2D | 0.17 | 3.57 (2.30, 4.31) | 0.61 | 24.49 (8.78, 29.42) | 0.84 |
| CCND1/FGF19/4/3 amplicon | 0.13 | 5.33 (1.15, 9.27) | 0.22 | 12.89 (3.65, 32.12) | 0.73 |
NGS, next-generation sequencing; UCSF, University of California, San Francisco; OS, overall survival; TTP, time to progression; CI, confidence interval; mTOR, mammalian target of rapamycin.